Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.

Learn more


For information relating to investor updates, financial information, share trading and presentations click the link below.

Investor News


Hexima is developing technology for use in transgenic plants to prevent damage by fungal pathogens and insect pests and for the treatment of fungal infections and non-melanoma skin cancer in humans.

Learn more

Hexima Share Price 30 June 2016

Shares in Hexima Limited are not traded on the ASX. The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2016, was at the price of $0.20 per share.

Hexima Presents Human Antifungal Technology Platform at ASM Microbe 2016

Hexima’s Chief Science Officer, Professor Marilyn Anderson, Onychomycosis Project Leader, Dr Michael Baker and Researcher, Dr Brigitte Hayes, have presented Hexima’s human antifungal technology at ASM Microbe 2016. The conference is an opportunity to showcase the benefits of Hexima’s technology and our progress towards clinical trials for fungal nail infections (onychomycosis). PhD Student Kathy Parisi also presented work relating to Hexima’s antifungal technology.

External Links

Take a look at these useful links to learn more about our industry.